Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 3, 2015, Pages 315-319

  Keangpraphun, T ^a   Towanabut, S ^b   Chinvarun, Y ^c   Kijsanayotin, P ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PRASAT NEUROLOGICAL INSTITUTE   (Thailand)

^c PRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

ABCB1 C3435T; phenobarbital; polymorphism; resistance; Thai patients with epilepsy

Indexed keywords

PHENOBARBITAL; ABCB1 PROTEIN, HUMAN; ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; EPILEPSY; FEMALE; FOCAL EPILEPSY; GENE; GENE FREQUENCY; GENERALIZED EPILEPSY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; NONHUMAN; PHENOTYPE; THAI (PEOPLE); TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE; GENETICS; GENOTYPE; MIDDLE AGED; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; THAILAND;

ADULT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE; EPILEPSY; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHENOBARBITAL; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND;

EID: 84928204713     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12263     Document Type: Article

References (43)

1. Thurman DJ, Beghi E, Begley CE, et al,. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia, 2011; 52 (Suppl. 7): 2-26.
2. World Health Organization (WHO). Epilepsy. Fact sheet, No. 999, 2012; Available from: http://www.who.int/mediacentre/factsheets/fs999/en/
3. Asawavichienjinda T, Sitthi-Amorn C, Tanyanont W,. Prevalence of epilepsy in rural Thailand: a population-based study. J Med Assoc Thai, 2002; 85: 1066-1073.
4. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ,. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia, 2005; 46: 643-647.
5. Szoeke C, Sills GJ, Kwan P, et al,. Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. Epilepsia, 2009; 50: 1689-1696.
6. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K,. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics, 2006; 7: 551-561.
7. Hoffmeyer S, Burk O, von Richter O, et al,. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000; 97: 3473-3478.
8. Sisodiya SM,. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol, 2003; 16: 197-201.
9. Kwan P, Brodie MJ,. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia, 2005; 46: 224-235.
10. Kwan P, Baum L, Wong V, et al,. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav, 2007; 11: 112-117.
11. Potschka H, Fedrowitz M, Loscher W,. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett, 2002; 327: 173-176.
12. Kwan P, Brodie MJ,. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia, 2004; 45: 1141-1149.
13. Lee SM, Chung JY, Lee YM, Park MS, Namgung R, Park KI, Lee C,. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child, 2012; 97: 569-572.
14. Siddiqui A, Kerb R, Weale ME, et al,. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med, 2003; 348: 1442-1448.
15. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH,. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics, 2005; 6: 411-417.
16. Ebid AH, Ahmed MM, Mohammed SA,. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit, 2007; 29: 305-312.
17. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH,. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics, 2007; 8: 1151-1158.
18. Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M,. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. Mol Biol Rep, 2014; 41: 331-336.
19. Tan NC, Heron SE, Scheffer IE, et al,. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology, 2004; 63: 1090-1092.
20. Kim DW, Kim M, Lee SK, Kang R, Lee S-Y,. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure, 2006; 15: 344-347.
21. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, Posavec A,. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure, 2008; 17: 524-530.
22. Pati S, Alexopoulos AV,. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Clevel Clin J Med, 2010; 77: 457-467.
23. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med, 2000; 342: 314-319.
24. Kwan P, Arzimanoglou A, Berg AT, et al,. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010; 51: 1069-1077.
25. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 1989; 30: 389-399.
26. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C,. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia, 1995; 36: 1-6.
27. Lin JH, Yamazaki M,. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet, 2003; 42: 59-98.
28. Gidal BE,. P-glycoprotein expression and pharmacoresistant epilepsy: cause or consequence? Epilepsy Curr, 2014; 14: 136-138.
29. Chowbay B, Li H, David M, Cheung YB, Lee EJ,. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol, 2005; 60: 159-171.
30. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM,. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 2007; 315: 525-528.
31. Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y,. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav, 2011; 21: 27-36.
32. Wang D, Sadee W,. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J, 2006; 8: E515-E520.
33. Buathet K, Chinvarun Y, Towanabut S, Kijsanayotin P,. Association of ABCB1 polymorphism with lamotrigine-resistant epilepsy in Thais. Thai J Pharm Sci, 2013; 37: 146-151.
34. Cheng JW, Zhang LJ, Hou YQ, Zhao Q, Zhang XJ, Chen XF, Bai Y,. Association between MDR1 C3435T polymorphism and refractory epilepsy in the Chinese population: a systematic review and meta-analysis. Epilepsy Behav, 2014; 36: 173-179.
35. Li M, Tan J, Yang X, et al,. The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy Res, 2014; 108: 1052-1067.
36. Haerian BS, Roslan H, Raymond AA, et al,. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure, 2010; 19: 339-346.
37. Cascorbi I, Gerloff T, Johne A, et al,. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther, 2001; 69: 169-174.
38. Tanabe M, Ieiri I, Nagata N, et al,. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 2001; 297: 1137-1143.
39. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ,. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics, 2003; 13: 89-95.
40. Ameyaw MM, Regateiro F, Li T, et al,. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 2001; 11: 217-221.
41. Mhaidat NM, Alshogran OY, Khabour OF, et al,. Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma. J Exp Clin Cancer Res, 2011; 30: 68.
42. Insaro M,. Association study of CYP2C9, CYP2C19 and ABCB1 genetic variants and non-genetic variants with phenytoin doses and blood levels in Thai epileptic patients: Chulalongkorn University; 2010.
43. Eadie MJ, Lander CM, Hooper WD, Tyrer JH,. Factors influencing plasma phenobarbitone levels in epileptic patients. Br J Clin Pharmacol, 1977; 4: 541-547.